Brand Change Reminder New Listings – 1 October 2019 & then Sole Supply – 1 March 2020
Click here to read the original notifications for Cetomacrogol with glycerol, Furosemide Tab 40 mg , Metoclopramide Inj, Paroxetine Tab, Povidone Iodine Antiseptic Soln 10% 15ml & 500 ml, Ropinirole Tab and Sertraline Tab.
Most of these products will have DUAL listings in the Pharmaceutical Schedule & where applicable HML from 1 October 2019 until 28 February 2020.
The exception being Metoclopramide Injection 5 mg per ml 2 ml 10 pack which will move to HSS and CSS status 1 January 2020.
Click here to read the original notification for Clindamycin Hydrochloride Cap 150 mg. The listing date has been bought forward to October 2019 due to potential supply issues with the incumbent brand. Nothing else changes so effectively this one will be a 6 month DUAL listing transition, depending on stock availability.
We ask that you continue to order the incumbent brand(s) to ensure supplies move through the supply chain with no risk to either pharmacy or wholesaler.
ProPharma /PWR will implement automatic replacement where applicable.
As of the date of this notification ProPharma / PWR cannot accept any of the products listed to be delisted for credit under any circumstances.
ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 March 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesale and pharmacy, do not need to experience potential losses during the transition period.
Together we can make this a seamless and painless transition.
We thank you in anticipation of your ongoing support.